Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
PEACHI-03 Clinical Trial Update
Following the completion of Work Package 1 (Production of clinical lots and approval for use in clinical trials), work has begun on PEACHI-03 (safety and immunogenicity of second generation viral vectored technology using ChAd3 and MVA, employing NSmut linked to the human MHC class II invariant chain, in both healthy subjects and DAA-treated patients).
Approval for the trial from the UK regulatory agencies was obtained in October 2017 and recruitment is scheduled to begin in November 2017.
For more news, click here.
The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection.
The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens. Read more about the project here...
This goal requires a multidisciplinary approach in which diverse expertise and technologies converge.
PEACHI is a unique consortium that consists of cutting edge clinical and scientific expertise, partnered with industry. In the last two years partnership members have employed viral vectored technology to develop the most immunogenic HIV-1 and HCV vaccines described to date.
If you have any questions regarding PEACHI please contact the team at the following email address: